SCHEMBL21643010

SCHEMBL21643010

N#Cc1csc(-c2csc(-c3csc(-c4csc(C[C@H](N)C(=O)O)n4)n3)n2)n1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 2/20 0.33
PKM P14618 2/20 0.33
MEN1 O00255 2/20 0.33
CYP3A4 P08684 2/20 0.33
HSD17B10 Q99714 2/20 0.33
CYP2C9 P11712 2/20 0.33
ALDH1A1 P00352 2/20 0.33
LMNA P02545 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
RGS12 O14924 1/20 0.33
ALOX15 P16050 1/20 0.33
NFKB1 P19838 1/20 0.33
CASP1 P29466 1/20 0.33
BRCA1 P38398 1/20 0.33
THPO P40225 1/20 0.33
CASP7 P55210 1/20 0.33
GNAI1 P63096 1/20 0.33
HIF1A Q16665 1/20 0.33
KDM4E B2RXH2 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21643032 1.00 USP2 (0.33) USP2PKMMEN1CYP3A4HSD17B10
SCHEMBL21643053 0.99 USP2 (0.33) USP2PKMMEN1CYP3A4HSD17B10
SCHEMBL21642995 0.89 EIF4E (0.34) PKMMEN1CYP2C9ALDH1A1LMNA
SCHEMBL21642993 0.89 EIF4E (0.34) PKMMEN1CYP2C9ALDH1A1LMNA
SCHEMBL21643014 0.87 GRIK1 (0.31) GRIK1GRIA1GRIA2GRIA3GRIA4
SCHEMBL21643011 0.87 GRIK1 (0.31) GRIK1GRIA1GRIA2GRIA3GRIA4
SCHEMBL21643021 0.84 TPH1 (0.39) MEN1ALDH1A1LMNAL3MBTL1KDM4E
SCHEMBL21643022 0.84 TPH1 (0.39) MEN1ALDH1A1LMNAL3MBTL1KDM4E
SCHEMBL21643049 0.82 GABRA5 (0.31) GRIA1GRIA3
SCHEMBL21643061 0.81 DPP4 (0.31) DPP4DPP8DPP9GRIK1GRIA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11319347-B2 Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound FUJIFILM CORPORATION (JP) 2022-05-03 US disclosed
US-20200040039-A1 PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND FUJIFILM CORPORATION (JP) 2020-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200040039-A1 PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND VIP, NPPA, NGLY1 USP2 3972/4885PKM 2870/4885MEN1 329/4885
US-11319347-B2 Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound VIP, NPPA, NGLY1 USP2 3972/4885PKM 2870/4885MEN1 329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.